Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union
- 1 December 2002
- journal article
- Published by Elsevier in Kidney International
- Vol. 62 (82) , S68-S72
- https://doi.org/10.1046/j.1523-1755.62.s82.14.x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Renal replacement therapy in Europe: the results of a collaborative effort by the ERA–EDTA registry and six national or regional registriesNephrology Dialysis Transplantation, 2001
- Epidemiology of end-stage renal disease: International comparisons of renal replacement therapyKidney International, 2000
- Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapiesNephrology Dialysis Transplantation, 1999
- Renal disease and hypertension in non–insulin-dependent diabetes mellitusKidney International, 1999
- Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projectionsDiabetes Care, 1998
- The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010Diabetic Medicine, 1997